×
About 4,234 results

ALLMedicine™ Immunodeficiencies Center

Research & Reviews  2,073 results

Common variable immunodeficiency with granulomatous-lymphocytic interstitial lung disea...
https://doi.org/10.1186/s12890-020-01231-6
BMC Pulmonary Medicine; Cowen JE, Stevenson J et. al.

Aug 1st, 2020 - Common variable immunodeficiency (CVID) is a group of heterogeneous primary immunodeficiencies characterised by a dysregulated and impaired immune response. In addition to an increased susceptibility to infection, it is also associated with noninf...

National external quality assessment for next-generation sequencing-based diagnostics o...
https://doi.org/10.1038/s41431-020-0702-0
European Journal of Human Genetics : EJHG; Elsink K, Huibers MMH et. al.

Jul 29th, 2020 - Dutch genome diagnostic centers (GDC) use next-generation sequencing (NGS)-based diagnostic applications for the diagnosis of primary immunodeficiencies (PIDs). The interpretation of genetic variants in many PIDs is complicated because of the phen...

Global systematic review of primary immunodeficiency registries.
https://doi.org/10.1080/1744666X.2020.1801422
Expert Review of Clinical Immunology; Abolhassani H, Azizi G et. al.

Jul 27th, 2020 - During the last 4 decades, registration of patients with primary immunodeficiencies (PID) has played an essential role in different aspects of these diseases worldwide including epidemiological indexes, policymaking, quality controls of care/life,...

Presence of Genetic Variants Among Young Men With Severe COVID-19.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382021
JAMA van der Made CI, Simons A et. al.

Jul 24th, 2020 - Severe coronavirus disease 2019 (COVID-19) can occur in younger, predominantly male, patients without preexisting medical conditions. Some individuals may have primary immunodeficiencies that predispose to severe infections caused by severe acute ...

The challenges presented by haematopoietic stem cell transplantation in children with p...
https://doi.org/10.1093/bmb/ldaa017
British Medical Bulletin; Gennery AR

Jul 14th, 2020 - For many primary immunodeficiencies (PIDs), haematopoietic stem cell transplantation (HSCT) offers treatment to cure disease. However, patients with PID present a unique set of challenges when considering HSCT. Review of recent literature. The mos...

see more →

Guidelines  1 results

Grifols announces FDA approval of Xembify®, 20% subcutaneous immunoglobulin for primary immunodeficiencies
https://www.grifols.com/en/view-news/-/news/grifols-announces-fda-approval-of-xembify-20-subcutaneous-immunoglobulin-for-primary-immunodeficiencies

Jul 4th, 2019 - Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, announced today that Xembify®, its new 20% subcutaneous immunoglobulin, has been approved by the U.S. Food and Drug Administration (FDA). Xembify® is ...

see more →

Drugs  23 results see all →

Clinicaltrials.gov  2,111 results

Common variable immunodeficiency with granulomatous-lymphocytic interstitial lung disea...
https://doi.org/10.1186/s12890-020-01231-6
BMC Pulmonary Medicine; Cowen JE, Stevenson J et. al.

Aug 1st, 2020 - Common variable immunodeficiency (CVID) is a group of heterogeneous primary immunodeficiencies characterised by a dysregulated and impaired immune response. In addition to an increased susceptibility to infection, it is also associated with noninf...

National external quality assessment for next-generation sequencing-based diagnostics o...
https://doi.org/10.1038/s41431-020-0702-0
European Journal of Human Genetics : EJHG; Elsink K, Huibers MMH et. al.

Jul 29th, 2020 - Dutch genome diagnostic centers (GDC) use next-generation sequencing (NGS)-based diagnostic applications for the diagnosis of primary immunodeficiencies (PIDs). The interpretation of genetic variants in many PIDs is complicated because of the phen...

Global systematic review of primary immunodeficiency registries.
https://doi.org/10.1080/1744666X.2020.1801422
Expert Review of Clinical Immunology; Abolhassani H, Azizi G et. al.

Jul 27th, 2020 - During the last 4 decades, registration of patients with primary immunodeficiencies (PID) has played an essential role in different aspects of these diseases worldwide including epidemiological indexes, policymaking, quality controls of care/life,...

Presence of Genetic Variants Among Young Men With Severe COVID-19.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382021
JAMA van der Made CI, Simons A et. al.

Jul 24th, 2020 - Severe coronavirus disease 2019 (COVID-19) can occur in younger, predominantly male, patients without preexisting medical conditions. Some individuals may have primary immunodeficiencies that predispose to severe infections caused by severe acute ...

The challenges presented by haematopoietic stem cell transplantation in children with p...
https://doi.org/10.1093/bmb/ldaa017
British Medical Bulletin; Gennery AR

Jul 14th, 2020 - For many primary immunodeficiencies (PIDs), haematopoietic stem cell transplantation (HSCT) offers treatment to cure disease. However, patients with PID present a unique set of challenges when considering HSCT. Review of recent literature. The mos...

see more →

News  23 results

Spotting immunodeficiency in the pediatric dermatology clinic
https://www.mdedge.com/dermatology/article/210332/rare-diseases/spotting-immunodeficiency-pediatric-dermatology-clinic?channel=39212
Jim Kling

Oct 17th, 2019 - SEATTLE – Immunodeficiency in children can look much like eczematous dermatitis. Be aware of this potential diagnosis.

Grifols announces FDA approval of Xembify®, 20% subcutaneous immunoglobulin for primary immunodeficiencies
https://www.grifols.com/en/view-news/-/news/grifols-announces-fda-approval-of-xembify-20-subcutaneous-immunoglobulin-for-primary-immunodeficiencies

Jul 4th, 2019 - Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, announced today that Xembify®, its new 20% subcutaneous immunoglobulin, has been approved by the U.S. Food and Drug Administration (FDA). Xembify® is ...

Novel transplant regimen improves survival in primary immunodeficiency
https://www.mdedge.com/hematology-oncology/article/195803/transplantation/novel-transplant-regimen-improves-survival?channel=50521
Sharon Worcester

Mar 6th, 2019 - HOUSTON – Allogeneic hematopoietic stem cell transplantation (allo-HCT) following a novel reduced-intensity conditioning regimen was largely successful in a heterogeneous cohort of 29 adults and children with primary immunodeficiency in a prospect.

A ‘highly effective’ strategy for haplo-HSCT
https://www.mdedge.com/hematology-oncology/article/184883/transplantation/highly-effective-strategy-haplo-hsct
Jen Smith

Jun 27th, 2018 - Daria Pagliara, MD, PhD STOCKHOLM—Researchers have identified a “highly effective” transplant strategy for pediatric patients with primary immunodeficiencies who lack a suitable HLA-compatible donor, according to a speaker at the 23rd Congress of.

FDA approves IVIG product for PI and chronic ITP
https://www.mdedge.com/hematology-oncology/article/186860/anemia/fda-approves-ivig-product-pi-and-chronic-itp
HT Staff

Feb 9th, 2017 - Vials of product Photo by Bill Branson The US Food and Drug Administration (FDA) has approved an intravenous immunoglobulin (IVIG) product (Gammaplex® 10%) for the treatment of primary immunodeficiency (PI) and chronic immune thrombocytopenia (ITP.

see more →

Patient Education  3 results see all →